Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Replidyne reverse merges with Cardiovascular Systems

Executive Summary

Right after withdrawing from its initial public offering, Cardiovascular Systems Inc. announced it has agreed to be acquired by infectious disease therapeutics developer Replidyne in a reverse merger. Once the stock swap is completed, CSI's shareholders will own 83% of the combined company, which will retain CSI's name.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies